UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial

Journal of clinical oncology, 2011-07, Vol.29 (20), p.2773-2780

2011

Volltextzugriff (PDF)

Immune check point inhibitors in BRAF mutated metastatic colorectal cancer: A review

International Journal of Gastrointestinal Intervention, 2024, 13(3), , pp.74-81

2024

Volltextzugriff (PDF)

Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell’Italia Meridionale

Journal of clinical oncology, 2005-08, Vol.23 (22), p.4866-4875

2005

Volltextzugriff (PDF)

Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2017-09, Vol.20 (5), p.825-833

2017

Volltextzugriff (PDF)

Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy

Biomedicines, 2022-04, Vol.10 (5), p.1035

2022

Volltextzugriff (PDF)

Reactions and countermeasures of medical oncologists towards the incoming COVID-19 pandemic: a WhatsApp messenger-based report from the Italian College of Chief Medical Oncologists

Ecancermedicalscience, 2020-05, Vol.14, p.1046-1046

2020

Volltextzugriff (PDF)

Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer

Neoplasia (New York, N.Y.), 2014-09, Vol.16 (9), p.751-756

2014

Volltextzugriff (PDF)

Merkel cell carcinoma responsive to Etoposide: a case report and brief literature review

Journal of cancer metastasis and treatment, 2016-08, Vol.2 (8), p.310

2016

Volltextzugriff (PDF)

Efficacy of A Fluoropyrimidine plus Mitomycin C in Pretreated Patients with Metastatic Colorectal Cancer Eligible for Regorafenib: A Retrospective Study

AIMS medical science, 2017-01, Vol.4 (4), p.456-464

2017

Volltextzugriff (PDF)

Totally Implanted Venous Access Devices Implanted in the Saphenous Vein. Relation Between the Reservoir Site and Comfort/Discomfort of the Patients

Annals of vascular surgery, 2012-11, Vol.26 (8), p.1127.e9-1127.e13

2012

Volltextzugriff (PDF)

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

The lancet oncology, 2020-04, Vol.21 (4), p.497-507

2020

Volltextzugriff (PDF)

Out-of-pocket costs in gastrointestinal cancer patients: Lack of a perfectly framed problem contributing to financial toxicity

Critical reviews in oncology/hematology, 2021-11, Vol.167, p.103501-103501, Article 103501

2021

Volltextzugriff (PDF)

Phase II Trial of Oxaliplatin and Tegafur/Uracil and Oral Folinic Acid for Advanced or Metastatic Colorectal Cancer in Elderly Patients

Oncology, 2005-01, Vol.69 (2), p.122-129

2005

Volltextzugriff (PDF)

Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma

International journal of radiation oncology, biology, physics, 2001-07, Vol.50 (3), p.651-658

2001

Volltextzugriff (PDF)

Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition

Clinical colorectal cancer, 2019-06, Vol.18 (2), p.125-132.e2

2019

Volltextzugriff (PDF)

Is G8 geriatric assessment tool useful in managing elderly patients with metastatic pancreatic carcinoma?

Journal of geriatric oncology, 2021-01, Vol.12 (1), p.163-167

2021

Volltextzugriff (PDF)

Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low‐Risk, Locally Advanced Rectal Cancer (RaP Study/STAR‐03)

The oncologist (Dayton, Ohio), 2018-08, Vol.23 (8), p.912-918

2018

Volltextzugriff (PDF)

Examining perceptions of financial toxicity among cancer patients: The Financial Toxicity 16 Questionnaire

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e19389-e19389

2020

Volltextzugriff (PDF)

Bevacizumab Plus Chemotherapy Cost Effectiveness

Journal of clinical oncology, 2015-11, Vol.33 (32), p.3840-3841

2015

Volltextzugriff (PDF)

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

The lancet oncology, 2005-06, Vol.6 (6), p.369-376

2005

Volltextzugriff (PDF)

Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.3508-3508

2019

Volltextzugriff (PDF)

Bevacizumab (B) + bi-weekly capecitabine (C) and oxaliplatin (O) (XELOX2) or FOLFOX4 in first-line treatment of metastatic colorectal cancer (mCRC): Final results of a multicenter randomized phase II trial of the Gruppo Oncologico dell’Italia Meridionale (GOIM protocol 2802)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3542-3542

2018

Volltextzugriff (PDF)

Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell’Italia Meridionale (GOIM 2802)

Clinical colorectal cancer, 2020-06, Vol.19 (2), p.109-115

2020

Volltextzugriff (PDF)

Clinical impact of neutropenia and febrile neutropenia in mCRC pts treated with FOLFOXIRI/bevacizumab (bev): A pooled analysis of TRIBE and TRIBE2 studies

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.11591-11591

2019

Volltextzugriff (PDF)

1 – 25 von 75

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(75)

Sprache

Englisch
(72)
Italienisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(44)
Science & Technology
(44)
Humans
(36)
Oncology
(34)
Male
(29)
Female
(28)
Aged
(27)
Middle Aged
(23)
Adult
(20)
Chemotherapy
(15)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(14)
Treatment Outcome
(14)
Colorectal Neoplasms - Drug Therapy
(11)
Neoplasm Staging
(11)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(10)
Biological And Medical Sciences
(10)
Colorectal Neoplasms - Pathology
(10)
Medical Sciences
(10)
Aged, 80 And Over
(9)
Colorectal Cancer
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial

Immune check point inhibitors in BRAF mutated metastatic colorectal cancer: A review

Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell’Italia Meridionale

Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world

Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy

Reactions and countermeasures of medical oncologists towards the incoming COVID-19 pandemic: a WhatsApp messenger-based report from the Italian College of Chief Medical Oncologists

Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer

Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer

Merkel cell carcinoma responsive to Etoposide: a case report and brief literature review

Efficacy of A Fluoropyrimidine plus Mitomycin C in Pretreated Patients with Metastatic Colorectal Cancer Eligible for Regorafenib: A Retrospective Study

Totally Implanted Venous Access Devices Implanted in the Saphenous Vein. Relation Between the Reservoir Site and Comfort/Discomfort of the Patients

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Out-of-pocket costs in gastrointestinal cancer patients: Lack of a perfectly framed problem contributing to financial toxicity

Phase II Trial of Oxaliplatin and Tegafur/Uracil and Oral Folinic Acid for Advanced or Metastatic Colorectal Cancer in Elderly Patients

Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma

Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition

Is G8 geriatric assessment tool useful in managing elderly patients with metastatic pancreatic carcinoma?

Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low‐Risk, Locally Advanced Rectal Cancer (RaP Study/STAR‐03)

Examining perceptions of financial toxicity among cancer patients: The Financial Toxicity 16 Questionnaire

Bevacizumab Plus Chemotherapy Cost Effectiveness

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC

Bevacizumab (B) + bi-weekly capecitabine (C) and oxaliplatin (O) (XELOX2) or FOLFOX4 in first-line treatment of metastatic colorectal cancer (mCRC): Final results of a multicenter randomized phase II trial of the Gruppo Oncologico dell’Italia Meridionale (GOIM protocol 2802)

Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell’Italia Meridionale (GOIM 2802)

Clinical impact of neutropenia and febrile neutropenia in mCRC pts treated with FOLFOXIRI/bevacizumab (bev): A pooled analysis of TRIBE and TRIBE2 studies

Suchergebnisse filtern